News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

Cardinal Health Receives Department of Defense Certification and Accreditation for Pyxis® Products
05/18/2005

SAN DIEGO, May 18, 2005 — Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, today announced it has achieved certification and accreditation through the U.S. Department of Defense Information Technology Security Certification and Accreditation Process (DITSCAP) for additional Pyxis® products. 

These products include the Pyxis CIISafe™ controlled substance management system, Pyxis MedStation® 3000 medication management system, Pyxis SupplyStation® supply management system and Pyxis Veri5® medication verification software application. Cardinal Health previously certified and accredited the Pyxis Connect™ physician order management system, Pyxis MAR™ software, Pyxis MedStation® 2000 system, Pyxis PARx® pharmacy auto-replenishment system and Pyxis SMART Remote Manager™ system.

Together, these Pyxis® products create a powerful system to increase patient safety, reduce medication errors and support regulatory compliance while enhancing the security and availability of medications and supplies in patient-care areas worldwide. Developed as a suite of complementary products, these systems are distributed to Department of Defense (DoD) commands in England, Iceland, Italy, Japan, Puerto Rico and South Korea, in addition to U.S. military bases.

"Cardinal Health acknowledges that information security is a vital concern in the health care industry,” said Dwight Winstead, president and chief operating officer of the Clinical Technologies and Services segment of Cardinal Health. “We are committed to providing our customers with secure products, which is why we use the stringent DITSCAP process as the standard to meet DoD requirements for certification and accreditation of information systems.”

About Cardinal Health
Cardinal Health, Inc. is the leading provider of products and services supporting the health care industry. Cardinal Health develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals, medical/surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 55,000 people on six continents and produces annual revenues of more than $65 billion. More information about the company may be found at www.cardinalhealth.com.


Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships or changes to the terms of those relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings, the impact of previously announced restatements, difficulties in opening new facilities or fully utilizing existing capacity, difficulties and uncertainties associated with business model transitions, including the conversion of margin generated from branded pharmaceutical manufacturers to non-contingent consideration, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statement.

 

More Company News
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

04/07/2021

By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health

04/07/2021

Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...

03/30/2021

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields